SNU66 Antibody

What is SNU66/SART1 and what are its primary cellular functions?

SNU66 (SNUrp associated protein) is a spliceosomal protein also known as SART1 (Squamous cell carcinoma antigen recognized by T cells 1). It was originally identified in human cells as an antigen recognized by cytotoxic T lymphocytes . The protein functions primarily as a component of the U4/U6-U5 tri-snRNP complex, one of the essential building blocks of the spliceosome responsible for pre-mRNA processing . The human SNU66 protein has a molecular mass of approximately 90 kDa, though it typically appears as a 110 kDa band in Western blots due to post-translational modifications . Beyond its critical role in splicing, SNU66 has been implicated in some studies as potentially influencing transcriptional processes, though in vitro splicing assays with human nuclear extracts have confirmed that its primary function is in splicing .

How does SNU66 contribute to the maintenance of splice site recognition?

SNU66 plays a crucial role in maintaining 5' splice site identity during spliceosome assembly. During splicing, the 5' splice site is initially recognized by U1 snRNA, which later leaves the spliceosome during assembly progression. SNU66 becomes essential at this point for maintaining the correct splice site identity as it is loaded into the catalytic site . Recent structural data has revealed that human SNU66 H734 interacts with tri-snRNP 27K (SNRP27) M141 to stabilize the U4/U6 quasi-pseudo knot at the base of the U6 snRNA ACAGAGA box in pre-B complex . Mutations at SNU66 H765 in C. elegans (equivalent to human H734) promote alternative 5' splice site usage, indicating its importance in splice site fidelity . These findings confirm a previously unrecognized role for the C-terminus of SNU66 in maintaining 5' splice site identity during the critical transition from initial recognition to catalytic activation.

What protein interactions does SNU66 form within the spliceosome?

SNU66 forms several key protein-protein interactions within the spliceosomal complex. In humans, SNU66 interacts with Hub1, a ubiquitin-like protein that binds non-covalently to proteins and is involved in splicing regulation . This interaction occurs through a single HIND (Hub1 interaction domain) motif in human SNU66, which is both necessary and sufficient for Hub1 binding . Additionally, SNU66 interacts with SNRP27 (tri-snRNP 27K) at specific amino acid positions (SNU66 H734 and SNRP27 M141 in humans) to stabilize the U4/U6 quasi-pseudo knot structure . In the human B complex spliceosome, the N-terminal half of SNU66 also interacts with UBL5, PRP6, and the switch loop and β-finger motifs of Prp8 . SNU66 also collaborates with other spliceosomal proteins like SF3A1 and SF3B1 that are integral to the spliceosome's functioning . These multiple interactions highlight SNU66's central role in spliceosomal assembly and function.

What are the optimal conditions for using SNU66/SART1 antibodies in Western blotting?

For optimal Western blotting with SNU66/SART1 antibodies, researchers should consider several technical parameters based on validated protocols. Based on available data, the recommended antibody concentration is approximately 1 μg/mL when using commercial antibodies like ab88583 . The predicted molecular weight of SNU66/SART1 is around 90 kDa, but the observed band typically appears at approximately 110 kDa on SDS-PAGE gels due to post-translational modifications . When preparing samples, cell lysates (such as from Jurkat cells) at a concentration of 25-50 μg total protein per lane have been successfully used for detection . For secondary antibody detection, anti-mouse IgG HRP conjugates work effectively at dilutions ranging from 1:5000 to 1:50000, depending on the sensitivity requirements and specific secondary antibody used . Researchers should validate these conditions with their specific antibody and sample type, potentially including positive controls such as SART1-transfected cell lysates alongside non-transfected controls to confirm specificity.

How should SNU66 antibodies be validated for research applications?

Thorough validation of SNU66 antibodies is critical for ensuring experimental reliability. A comprehensive validation approach should include multiple complementary techniques:

• Western blot analysis: Compare detection in both endogenous samples (e.g., Jurkat cell lysates) and overexpression systems (e.g., SART1-transfected 293T cells) . Verify the expected band size (approximately 110 kDa for human SNU66/SART1) and ensure specificity by confirming absence of non-specific bands.

• Knockdown/knockout verification: Perform siRNA-mediated knockdown or CRISPR/Cas9 knockout of SNU66/SART1 and confirm reduced or absent signal, respectively. Previous studies have successfully used siRNA targeting SNU66, which can serve as a negative control for antibody specificity .

• Immunoprecipitation coupled with mass spectrometry: Validate that the antibody can successfully immunoprecipitate SNU66/SART1 and its known interaction partners (such as components of the U4/U6.U5 tri-snRNP complex).

• Immunofluorescence microscopy: Confirm the expected nuclear localization pattern, particularly in nuclear speckles where splicing factors typically concentrate . The antibody should show patterns consistent with other splicing factors.

• Cross-reactivity testing: If working with multiple species, confirm reactivity with the target species and assess potential cross-reactivity with homologs from other species based on sequence conservation.

What cellular fractionation methods are most effective when studying SNU66?

Since SNU66/SART1 is predominantly a nuclear protein associated with the spliceosome, effective cellular fractionation is crucial for its study. The following approach is recommended:

• Nuclear-cytoplasmic fractionation: Begin with a standard nuclear-cytoplasmic separation using hypotonic buffer followed by nuclear lysis. Since SNU66 is a component of the spliceosome, it should be predominantly found in the nuclear fraction .

• Subnuclear fractionation: For more detailed analysis, separate the nuclear fraction into nucleoplasmic and chromatin-bound fractions using salt extraction. SNU66 should be detected primarily in the nucleoplasmic fraction with the spliceosomal components.

• Spliceosomal complex isolation: For specialized studies, isolate spliceosomal complexes using immunoprecipitation of core spliceosomal components (such as U5 snRNP proteins) or density gradient ultracentrifugation to separate different spliceosomal assembly intermediates.

• Preservation of protein-protein interactions: If studying SNU66 interactions (such as with Hub1 or SNRP27), use gentle extraction conditions with non-ionic detergents and physiological salt concentrations to maintain these interactions .

• Quality control: Validate the fractionation using markers for different cellular compartments: GAPDH for cytoplasm, lamin B1 for nuclear envelope, and U1-70K for spliceosomal components.

Each fraction should be analyzed by Western blotting with the validated SNU66 antibody to determine the distribution and associations of the protein within the cell.

How can researchers investigate the role of SNU66 in alternative splicing regulation?

Investigating SNU66's role in alternative splicing requires a multi-faceted approach:

• High-throughput RNA sequencing: Perform RNA-seq on control and SNU66-depleted or mutated cells to identify global changes in splicing patterns. Previous studies have shown that mutations in SNU66 specifically affect alternative 5' splice site usage for numerous genes . RNA isolated from three biologically independent samples should be used for library preparation and deep sequencing with paired-end reads to accurately capture splice junctions .

• Bioinformatic analysis of splicing changes: Analyze sequencing data to identify different categories of alternative splicing events affected by SNU66 manipulation, including alternative 5' splice site (A5) events and intron retention (IR) events. In previous studies, researchers identified 83 alternative 5'ss events for SNU66(H765G) mutants that met stringent criteria for analysis .

• Experimental validation: Confirm selected alternative splicing events using RT-PCR with labeled primers followed by gel electrophoresis. This approach has shown high concordance with high-throughput sequencing analysis for SNU66-mediated alternative splicing events .

• Mechanism investigation: To understand how SNU66 maintains 5' splice site identity, examine its interaction with SNRP27 using co-immunoprecipitation with SNU66 antibodies followed by Western blotting or mass spectrometry. Double mutants of snrp-27(M141T) and snu-66(H765G) have been reported to be homozygous lethal, suggesting the crucial nature of this interaction .

• Splicing reporter assays: Develop minigene constructs containing alternative 5' splice sites to test the direct impact of SNU66 mutations or depletion on splice site selection in a controlled context.

What is the relationship between SNU66 and Hub1, and how can it be studied?

The relationship between SNU66 and Hub1 (a ubiquitin-like protein) represents an important aspect of splicing regulation that can be studied using several approaches:

• Mapping interaction domains: Previous research has shown that human SNU66 contains a single HIND (Hub1-interaction domain) motif that is both necessary and sufficient for Hub1 binding . Researchers can create truncation mutants of SNU66 to further characterize this interaction by removing or mutating the HIND domain, followed by co-immunoprecipitation with Hub1.

• Co-immunoprecipitation studies: Use SNU66 antibodies to immunoprecipitate the protein complex from nuclear extracts, followed by Western blotting for Hub1 to confirm their association in vivo. The reverse approach using Hub1 antibodies can also validate this interaction.

• Functional consequences of disrupting the interaction: Employ targeted mutations in the HIND domain of SNU66 that specifically disrupt Hub1 binding without affecting other functions. Then analyze the impact on splicing using RNA-seq and RT-PCR validation as described above.

• Splicing assays in vitro: Perform in vitro splicing assays using nuclear extracts depleted of SNU66 and complemented with either wild-type or Hub1-binding deficient SNU66 to directly assess the functional importance of this interaction for splicing catalysis.

• Localization studies: Use immunofluorescence with SNU66 and Hub1 antibodies to examine their co-localization in nuclear speckles or other subnuclear structures, and how this changes under conditions that affect splicing (such as transcriptional inhibition or heat shock).

• Structural studies: For advanced characterization, perform structural analysis of the SNU66-Hub1 complex using techniques like X-ray crystallography or cryo-EM to understand the molecular basis of their interaction and how it might influence spliceosome assembly.

How does SNU66 dysfunction contribute to splicing-related diseases?

The implication of SNU66 dysfunction in disease contexts is an emerging area of research that can be approached through several methodologies:

• Analysis of patient samples: Use SNU66 antibodies to assess protein expression and localization in tissues from patients with splicing-related disorders such as certain cancers or neurodegenerative diseases. Changes in expression levels or subcellular distribution could indicate a role in pathogenesis.

• Correlation with splicing defects: Analyze RNA-seq data from patient samples to identify aberrant splicing patterns that correlate with SNU66 expression or mutation status. Previous research has shown that SNU66 mutations affect alternative 5' splice site usage and intron retention, which are associated with diseases like Alzheimer's disease and cancer .

• Disease modeling: Create cellular or animal models with SNU66 mutations found in patients or with SNU66 depletion to recapitulate disease phenotypes. For example, intron retention events promoted by SNU66 mutation have been implicated in cancer and neurodegenerative disorders .

• Therapeutic targeting assessment: Use SNU66 antibodies to evaluate the effects of splicing modulators on SNU66-containing spliceosomal complexes, which could inform therapeutic approaches for splicing-related diseases.

• SNU66 as a biomarker: Investigate whether SNU66 protein levels or post-translational modifications change in disease states, potentially serving as a diagnostic or prognostic biomarker. This is particularly relevant given that SART1 was originally identified as a tumor antigen recognized by cytotoxic T lymphocytes .

• Genetic screening: Perform genetic screening in patient populations with splicing-related disorders to identify potential mutations in SNU66 that might contribute to disease pathogenesis, followed by functional validation using the approaches described above.

What controls should be included when working with SNU66 antibodies?

Proper experimental controls are essential for generating reliable results with SNU66 antibodies:

• Positive controls: Include lysates from cells known to express SNU66/SART1 at detectable levels, such as Jurkat cells . For overexpression studies, SART1-transfected cell lysates provide an excellent positive control .

• Negative controls: Include samples with SNU66 knockdown or knockout to confirm antibody specificity. Previous studies have used siRNA targeting SNU66, which resulted in nuclear accumulation of poly-adenylated RNA similar to when splicing is inhibited by other means .

• Loading controls: Use appropriate loading controls based on the cellular fraction being analyzed – GAPDH or β-actin for total lysates, lamin B1 for nuclear fractions, and specific spliceosomal proteins (like U5-116K) when analyzing spliceosomal complexes.

• Isotype controls: Include the appropriate isotype control antibody at the same concentration as the SNU66 antibody to identify any non-specific binding, particularly for immunoprecipitation or immunofluorescence experiments.

• Cross-reactivity controls: If the experimental design involves multiple species, include samples from those species to confirm the expected cross-reactivity or lack thereof, based on sequence conservation and the epitope recognized by the antibody.

• Technical controls: For each application, include technical controls specific to the method – for Western blotting, a molecular weight ladder; for immunofluorescence, a secondary-only control to assess background fluorescence.

How can researchers differentiate between effects on general splicing versus alternative splicing when studying SNU66?

Distinguishing between general splicing defects and specific alterations in alternative splicing when studying SNU66 requires careful experimental design:

What are the best approaches for studying SNU66 interactions with other spliceosomal proteins?

Studying SNU66's interactions with other spliceosomal proteins requires specialized approaches:

• Co-immunoprecipitation with SNU66 antibodies: Use validated SNU66 antibodies to pull down protein complexes from nuclear extracts, followed by Western blotting or mass spectrometry to identify interaction partners. This approach has been used to confirm interactions between SNU66 and Hub1 .

• Reciprocal co-immunoprecipitation: Perform the reverse experiment using antibodies against known or suspected interaction partners (such as SNRP27 or Hub1) to confirm the interaction from both perspectives.

• Proximity labeling: Employ BioID or APEX2 proximity labeling by fusing the enzyme to SNU66 to identify proteins in close proximity within the native cellular context, which is particularly valuable for studying dynamic spliceosomal interactions.

• Yeast two-hybrid or mammalian two-hybrid assays: Use these systems to test direct interactions between SNU66 and other spliceosomal proteins, as well as to map interaction domains by testing truncated or mutated versions of the proteins.

• Structural studies of complexes: Utilize cryo-EM or X-ray crystallography to determine the structural basis of SNU66 interactions within the spliceosome. Previous structural data has revealed the interaction between human SNU66 H734 and SNRP27 M141 in stabilizing the U4/U6 quasi-pseudo knot .

• In vitro binding assays: Perform in vitro binding assays using recombinant proteins to characterize direct interactions and determine binding affinities, which can help prioritize which interactions are most likely to be functionally significant.

• Functional validation: Confirm the functional significance of identified interactions by creating targeted mutations that specifically disrupt individual interactions and assessing the impact on splicing activity. For example, double mutants of snrp-27(M141T) and snu-66(H765G) have been shown to be homozygous lethal, indicating the essential nature of this interaction .

How might post-translational modifications of SNU66 regulate its function?

Post-translational modifications (PTMs) of SNU66 represent an understudied area with potential regulatory implications:

• Mass spectrometry-based PTM mapping: Use immunoprecipitation with SNU66 antibodies followed by mass spectrometry analysis to identify and map PTMs on SNU66. The observed difference between the predicted molecular weight (90 kDa) and the apparent size on Western blots (110 kDa) suggests significant post-translational modification .

• Phosphorylation analysis: Since many spliceosomal proteins are regulated by phosphorylation during the splicing cycle, use phospho-specific antibodies or Phos-tag SDS-PAGE followed by Western blotting with SNU66 antibodies to detect phosphorylated forms of the protein.

• PTM dynamics during splicing: Analyze how SNU66 modifications change during spliceosome assembly and catalysis by isolating spliceosomal complexes at different stages using established biochemical approaches, followed by Western blotting or mass spectrometry.

• Functional consequences of PTMs: Generate phosphomimetic or phospho-null mutants of SNU66 at identified modification sites and assess their impact on protein interactions, localization, and splicing activity using the methodologies described in previous sections.

• PTM crosstalk with other spliceosomal components: Investigate whether modifications of SNU66 correlate with or influence modifications of other spliceosomal proteins, particularly its direct interaction partners like SNRP27.

• Regulation of PTMs: Identify the enzymes (kinases, phosphatases, etc.) responsible for adding or removing modifications on SNU66 using inhibitor studies or enzyme knockdown approaches, followed by analysis of SNU66 modification status.

What role might SNU66 play in coupling splicing to other nuclear processes?

SNU66 may function beyond its established role in splicing to coordinate with other nuclear processes:

• Chromatin immunoprecipitation (ChIP): Use SNU66 antibodies for ChIP experiments to determine if SNU66 associates with chromatin, potentially indicating a role in co-transcriptional splicing. This is particularly relevant given that SNU66 may also bind to DNA .

• Co-immunoprecipitation with transcription factors: Investigate potential interactions between SNU66 and transcription machinery components using co-immunoprecipitation with SNU66 antibodies followed by Western blotting or mass spectrometry.

• RNA immunoprecipitation (RIP) or CLIP-seq: Perform RIP or CLIP-seq experiments with SNU66 antibodies to identify RNA targets and determine if SNU66 has preferences for specific transcript classes or genomic contexts.

• Nuclear fractionation coupled with proteomics: Isolate different nuclear compartments (nucleoplasm, chromatin, nuclear speckles) and analyze the distribution of SNU66 using antibodies, potentially identifying novel associations with non-splicing complexes.

• Live-cell imaging: Use fluorescently tagged SNU66 combined with markers for different nuclear processes to track its dynamics and potential co-localization with transcription sites, DNA damage foci, or other nuclear structures.

• Functional coupling experiments: Manipulate transcription rates or introduce DNA damage and examine how these perturbations affect SNU66 localization, interactions, or splicing activity to identify potential coupling mechanisms.

• Explore connection to unfolded protein response: Investigate the suggested connection between SNU66 and the unfolded protein response in mitochondria (UPRmt), which was indicated by genetic screens in C. elegans identifying Hub1, a SNU66-interacting protein, as being implicated in this pathway .